<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306774</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR051361</org_study_id>
    <secondary_id>R01AR051361</secondary_id>
    <nct_id>NCT00306774</nct_id>
  </id_info>
  <brief_title>Vitamin D to Slow Progression of Knee Osteoarthritis</brief_title>
  <official_title>Trial of Vitamin D to Reduce the Progression of Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Once Daily Dosing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee osteoarthritis (OA) is a common and disabling health problem in older adults and for&#xD;
      which there is no cure. The purpose of this study is to determine the effects of vitamin D on&#xD;
      knee OA symptoms and physical function in adults aged 45 years and older.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptomatic knee OA is one of the most frequent causes of limitation in lower limb tasks,&#xD;
      especially in the elderly. Knee OA causes 68 million lost work days per year. OA is the most&#xD;
      frequent reason for joint replacement, at a cost of billions of dollars per year. There are&#xD;
      currently no completely effective medical remedies for OA. Pharmaceutical companies are&#xD;
      trying to develop drugs that will slow the disease progression of OA; however, such&#xD;
      medications will be expensive to use in a population in which OA is common. There is evidence&#xD;
      that vitamin D supplementation, a simple and much cheaper intervention, may prove useful in&#xD;
      slowing the progression of OA. Even if only modestly effective, it could have considerable&#xD;
      impact in terms of reducing the societal burden of OA. Therefore, in the interests of public&#xD;
      health, the efficacy of vitamin D supplementation as a disease-modifying treatment for OA&#xD;
      needs to be tested in a rigorous clinical trial. Disease modification trials for knee OA have&#xD;
      been difficult in the past due to limitations of radiographic techniques. Fortunately,&#xD;
      magnetic resonance imaging (MRI) has emerged as a valid, precise, and reproducible tool for&#xD;
      the measurement of damage of cartilage and joint structures. The purpose of this study is to&#xD;
      evaluate the effects of vitamin D on knee OA symptoms and physical function in older adults.&#xD;
&#xD;
      Patients with symptomatic knee OA will be randomly assigned to receive vitamin D at 2,000&#xD;
      International Units (IU) a day or placebo. Each participant will be in the study for about 2&#xD;
      years. During that time, there will be 9 scheduled study visits (screening, Months 0, 2, 4,&#xD;
      8, 12, 16, 20, and 24) and interim safety visits as needed. Measurements of vital signs, a&#xD;
      knee exam, blood and urine collection, pill counts, and completion of questionnaires will&#xD;
      occur at all visits. Participants' physical function will be assessed at study entry and&#xD;
      Months 0, 12, and 24. MRI, bone density scanning, and an assessment by the study staff will&#xD;
      occur at Months 0, 12, and 24. Knee x-rays will occur at study screening and Month 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cartilage volume loss (MRI)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee symptoms (WOMAC questionnaire)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological (MRI) severity global score</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive vitamin D (cholecalciferol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (cholecalciferol)</intervention_name>
    <description>2,000 IU vitamin D capsule per day for 2 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule per day for 2 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic knee discomfort based on affirmative response to the question &quot;During the past&#xD;
             12 months, have you had pain, aching, or stiffness in or around your knee(s) on most&#xD;
             days for at least one month?&quot;&#xD;
&#xD;
          -  WOMAC pain subscale score of at least 1&#xD;
&#xD;
          -  Tibiofemoral OA on posterior anterior (PA) weight-bearing semi-flexed knee radiographs&#xD;
             with severity equivalent to Kellgren and Lawrence grade of at least 2&#xD;
&#xD;
          -  Clinical examination confirming knee pain or discomfort referable to the knee joint&#xD;
&#xD;
          -  Prepared to refrain from use of glucosamine, chondroitin, MSM, DMSO, and doxycycline&#xD;
&#xD;
          -  Pass faintness of heart trial period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum 25(OH) vitamin D level greater than 80 ng/ml&#xD;
&#xD;
          -  Use of glucosamine, chondroitin, or doxycycline within 3 months of random assignment&#xD;
&#xD;
          -  Use of MSM, DMSO within 3 months of random assignment&#xD;
&#xD;
          -  Use of vitamin D supplements such that the total daily dose is greater than 1,000 IU&#xD;
             or a single source is greater than 800 IU&#xD;
&#xD;
          -  Intra-articular joint injections (e.g., glucocorticoid or haluronic acid formulations,&#xD;
             within 3 months of random assignment)&#xD;
&#xD;
          -  Chronic glucocorticoid use&#xD;
&#xD;
          -  Hypercalcemia (total serum calcium greater than 10.5 mg/dL)&#xD;
&#xD;
          -  Hypercalcuria (spot urine calcium: creatinine ratio of 0.275 for women and 0.325 for&#xD;
             men, corresponding to 24-hour calcium excretion of 0.30 and 0.35 g, respectively)&#xD;
&#xD;
          -  Estimated GFR less than 30&#xD;
&#xD;
          -  Hyperparathyroidism (PTH greater than 65 pg/mL)&#xD;
&#xD;
          -  History of lymphoma or sarcoidosis&#xD;
&#xD;
          -  Reiter's syndrome&#xD;
&#xD;
          -  Psoriatic arthritis&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Ankylosing spondylitis&#xD;
&#xD;
          -  Currently on treatment for tuberculosis&#xD;
&#xD;
          -  Malabsorption disorders (e.g., advance liver disease, chronic renal disease-stage 4 or&#xD;
             5, Crohn's disease, Whipple's disease, celiac sprue)&#xD;
&#xD;
          -  Serious medical conditions or impairments that, in the view of the investigator, would&#xD;
             obstruct study participation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Plan to permanently relocate from the region during the trial period&#xD;
&#xD;
          -  Planned knee or hip arthroplasty during the study period&#xD;
&#xD;
          -  Any contra-indication to having an MRI scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy E. McAlindon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center, Division of Rheumatology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wang, J., Nuite, M., Wheeler, L.M., Badiani, P., Joas, J., McAdams, E.L., Fletcher, J., LaValley, M.P., Dawson-Hughes, B., McAlindon, T.E. Low Vitamin D Levels are Associated with Greater Pain and Slow Walking Speed in Patients with Knee Osteoarthritis (KOA). ACR Abstract #199 Arthritis &amp; Rheumatism. 2007;56: 9 (supplement): S124.</citation>
  </results_reference>
  <results_reference>
    <citation>Nuite, M., Wang, J., Wheeler, L.M., Fletcher, J., Badiani, P., McAdams, E.L., Joas, J., LaValley, M.P., Dawson-Hughes, B., McAlindon, T.E. Don't Always Believe What You Are Told: A comparison of Self-Reported with Measured Weight and Height. ARHP Abstract #2049 Arthritis &amp; Rheumatism. 2007;56: 9 (supplement): S779.</citation>
  </results_reference>
  <results_reference>
    <citation>L. M. Wheeler, J. Wang, M. Nuite, J. Fletcher, P. Badiani, E. L. McAdams, J. P. Joas, M. P. LaValley, B. Dawson-Hughes, T. E. McAlindon. Report of Daily Vitamin D Supplement Use is No Guarantee of Protection Against Vitamin D Deficiency in Knee Osteoarthritis Patients. OARSI Abstract #248 Osteoarthritis and Cartilage. 2007. Vol. 15 (Supplement A)</citation>
  </results_reference>
  <results_reference>
    <citation>G.H. Lo, M.H. Smith, E.L. McAdams, K.A. Carr, M. Nuite, B. Dawson-Hughes, N. Palermo, T.E. McAlindon. Baseline Vitamin D Status is Predictive of Longitudinal Change in Tibial BMD in Knee Osteoarthritis (OA). ACR Abstract #193 Arthritis &amp; Rheumatism. 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>E.L. McAdams, G.H. Lo, L.L. Price, M.H. Smith, K.A. Carr, M. Nuite, J.P. Joas, T.E. McAlindon. Varus-Valgus Static Malalignment does Not Predict Changes in Physical Function over a 1-year Period in People with Knee Osteoarthritis (OA). ACR Abstract #194 Arthritis &amp; Rheumatism. 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>M.H. Smith, G.H. Lo, M. Nuite, E.L. McAdams, K.A. Carr, J.P. Joas, B. Dawson-Hughes, N. Palermo, T.E. McAlindon. Increased Medial Tibial Bone Mineral Density (BMD) is Associated with Deterioration in Walking Ability and Pain in Individuals with Knee Osteoarthritis (KOA). ACR Abstract #697 Arthritis &amp; Rheumatism. 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Lo G.H., McAdams E., Smith M., Carr K., Nuite M., Dawson-Hughes B., Palermo N., McAlindon T.E. Tibial Plateau Proximal and Distal Bone Behave Similarly: Both Are Associated with Features of Knee Osteoarthritis (KOA). OARSI Abstract #137 Osteoarthritis and Cartilage. 2008. Vol. 16 (Supplement 4)</citation>
  </results_reference>
  <results_reference>
    <citation>Hansberry S., Lo G., Carr K., McAlindon T., Ward R., Nuite M., Schneider E. Comparing Quantitative v. Semi-Quantitative Analysis of Cartilage Degradation and Its Association with Knee Pain. Poster # 1072 from Transactions of the 55th Annual Meeting of the Orthopaedic Research Society (ORS), Las Vegas, Feb. 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Grace H. Lo, Timothy E. McAlindon, Kimberly A. Carr, Melanie A. Ripley, Melynn Nuite, William F. Harvey. Varus Thrust Is Associated with Pain in Knee Osteoarthritis. Arthritis and Rheumatism. 2009; 60:10(supplement) S310, Abstract #831</citation>
  </results_reference>
  <results_reference>
    <citation>W.F. Harvey, J.Y. Lee, K.A. Carr, M.A. Ripley, M. Nuite, T. E. McAlindon, G.H. Lo. Varus Thrust Is Associated with Cartilage Loss in Knee Osteoarthritis. Arthritis and Rheumatism. 2009; 60:10(supplement) S77, Abstract #211</citation>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>vitamin D</keyword>
  <keyword>knee pain</keyword>
  <keyword>cartilage loss</keyword>
  <keyword>WOMAC</keyword>
  <keyword>MRI</keyword>
  <keyword>cartilage volume</keyword>
  <keyword>OA</keyword>
  <keyword>physical function</keyword>
  <keyword>web-based</keyword>
  <keyword>internet-based</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

